BioCurex, Inc.(fka BOCX)

[Kag]

First, I have appreciated reading the research work done by Great-Grandma and Fluffy.

Here are three important things to consider:

1. I have posted this before but it is worth repeating. When I talked to a person in the lab testing section of a large, regional medical center a couple of months ago, I was told that approximately 95% of their tests were currently being ran on automated analyzers. The medical center happens to use two Bayer analyzers. In the future that percentage will only increase because it reduces errors, and by reducing the number of needed lab technicians, it also reduces the cost of health care.

2. Why can we as investors in BioCurex be assured that the chances are very good that Abbott will be successful in implementing serum RECAF tests on their Architect analyzer? Because Abbott has had the serum RECAF technology in their hands for over a year, and if it were not possible, Abbott would have stopped wasting the time and salary expense of their research experts a long time ago. Abbott would have already returned the technology by now.

3. Here is a link which shows how quick the FDA gives 510k approvals to run assays on different automated analyzers. It involved a "substantial equivalence" determination by the FDA . It was received by the FDA on Oct. 4, 2004 and approved on Dec. 22, 2004. This is the CA 15-3 assay that is currently being ran on Abbott's Architect analyzer which is used in the management of stage II and III breast cancers. http://www.fda.gov/cdrh/pdf4/k042732.pdf
kag